Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30, 2025

About this update from Median Technologies

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF’s General Regulations. SOPHIA ANTIPOLIS, France, December 03, 2025 --( BUSINESS WIRE )--Regulatory News: Median Technologies (Paris:ALMDT): (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20251203328402/en/ Contacts Median Technologies Emmanuelle Leygues VP, Corporate Marketing & Financial Communications +33 6 10 93 58 88 [email protected] Investors - ACTIFIN Ghislaine Gasparetto +33 6 85 36 76 81 [email protected] Press – Ulysse Communication Bruno Arabian +33 6 87 88 47 26 [email protected] Nicolas Entz +33 6 33 67 31 54 [email protected]

View stock analysis, news, and events for Median Technologies